ASX-listed Echo IQ has obtained regulatory approval in the United States for its AI-driven solution that supports structural heart disease diagnosis.
WHAT IT'S ABOUT
Two years since coming to the US, the company has now received 510(k) clearance from the Food and Drug Administration for EchoSolv AS, which is specifically indicated to support the diagnosis of severe aortic stenosis (a form of...
The digital health arm of India-based pharmaceutical company Lupin has unveiled its e-clinic attending to heart failure patients.
Called Lyfe, the virtual clinic is manned by a team of paramedics, nurses, cardiotherapists, health coaches and care managers who support cardiologists in managing their patients. Without specifying, Lupin Digital Health said the clinic is equipped with AI-guided...
UK-based Ultromics announced Tuesday that its machine learning-based decision-support system used to help detect heart failure with preserved ejection fraction had received FDA 510(k) clearance.
EchoGo Heart Failure, which was developed in partnership with the Mayo Clinic, aids physicians in diagnosing the condition by providing them with echocardiogram imaging results in people over 25 years old...
When Apple announced its Series 6 Watch wearable last month, with new features, including VO2 Max and blood oxygenation sensors, the tech giant also announced three new clinical studies that would use the device.
We expounded on one, an asthma study, in collaboration with Anthem, last month. But the other two, focused on heart failure and respiratory conditions like flu, respectively, have not...
A research programme led by US-based non-profit medical centre Mayo Clinic and UK health tech firm Ultromics will apply AI to forecast heart failure.
The team will use AI analysis of ultrasound heart scans to identify the markers of heart failure and alert doctors to potential heart failure.
WHY IT MATTERS
The aim is to develop a diagnostic and predictive tool that can reduce misdiagnosis and...
This morning maker of heart failure management and remote monitoring devices Endotronix scored $45 million in a Series D financing round led by LSP, with participation from Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors, Wanxiang Healthcare Investments, and an unnamed corporate investor.
“We are thrilled with the world-...
A new study, sponsored by the US Department of Veterans Affairs, applied wearable biosensors to post-acute heart failure patients and deployed FDA-cleared analytics from vendor physIQ to detect vital sign anomalies.
It demonstrated promising predictive power for artificial intelligence-based analytics in terms of sensitivity, specificity and early warning lead time – suggesting the potential to...
Intermountain Healthcare researchers have created a new app to monitor heart failure patients and identify when their condition becomes advanced.
The app monitors medical tests and health status and quickly alerts clinicians that the heart patient’s care needs have changed. When computer monitoring indicates a patient likely has advanced heart failure, the app automatically sends a secure email...
The Duke Clinical Research Institute, funded by a grant from Novartis, is launching a large-scale study to explore the effectiveness of mobile apps in the treatment of heart failure patients. The study, called Connect HF, is aiming to enroll 8,000 patients across 160 hospitals by the end of fall 2018, with results hoped for by the end of 2020.
"CONNECT HF is a clinical trial looking at different...
San Francisco-based ReThink Medical raised $3 million to develop a medical wearable to predict and prevent heart failure. The round was led by Emergent Medical with additional funding from Norwich Ventures and Launch Capital. The company is also operating with a previously-awarded NIH grant as well as a strategic partnership with Japanese medical device company Terumo Corporation, which includes...
